ELCC 2017 | Increasing treatment options for NSCLC

David Gandara

David Gandara, MD from the University of California, Davis, CA discusses the recent change in the treatment landscape of advanced non-small cell lung cancer (NSCLC) and what we can expect in the future. There have been great advances in the treatment of advanced NSCLC, however an increase in the number of treatment options brings rise to new challenges and questions that need to be dealt with. This interview was recorded at the annual meeting of the European Lung Cancer Conference (ELCC) 2017, Geneva, Switzerland.

Share this video  
Similar topics
Related videos
1:46
Is lorlatinib a better option for NSCLC?
Benjamin Besse
1:54
Balancing the benefits and costs of immunotherapy in the treatment of lung cancer
Rolf Stahel
0:51
Summary of nurse-led follow-up service for prostate cancer patients on Radium-223
Lisa White
1:34
How can we optimize contemporary bladder cancer care?
Morgan Roupret
5:02
Going beyond PD-L1 testing for lung cancer immunotherapy
Juergen Wolf
Lung Cancer
ELCC 2017
Interview
5th May 2017
More from David Gandara
PD-L1 agents in the treatment of NSCLC
Phase II study of Durvalumab for patients with NSCLC
Current treatment options for squamous cell lung cancer
VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJOncology is intended for healthcare professionals